PDB31 TOTAL COST REDUCTION IN TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS TREATED WITH PIOGLITAZONE (PIO) BASED THERAPIES VERSUS NON-THIAZOLIDINEDIONE (NON-TZD) BASED THERAPIES
Nov 1, 2007, 00:00 AM
10.1016/S1098-3015(10)64979-0
https://www.valueinhealthjournal.com/article/S1098-3015(10)64979-0/fulltext
Section Title :
Section Order :
138
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)64979-0&doi=10.1016/S1098-3015(10)64979-0